Background
Esophageal cancer is one of the most aggressive cancers and is the sixth leading cause of cancer death worldwide. Currently, there are limited clinical approaches for the early diagnosis and treatment of esophageal cancer, resulting in only a 10% five-year survival rate for patients. It can be hoped, that the identification of novel biological markers and tumorigenic pathways will improve therapeutic strategies for esophageal cancer patients.
RBM3 is a glycine-rich RNA-binding protein and part of the family of cold shock proteins [
1]. Proteins from this family are induced by various environmental stresses, including hypoxia [
2] and cold [
2‐
4]. RBM3 bind to DNA and RNA [
5] and is involved in maintenance of DNA integrity, including DNA-dependent replication, DNA replication, chromatin remodeling, DNA integrity checkpoints [
6] and regulation of RNA metabolism, including splicing, stability and transport of mRNA [
1].
In cancer there are multiple contradictory reports regarding the role and expression of RBM3. RBM3 has been suggested to have potential proto-oncogene and tumor suppressive roles in cancer. RBM3 expression leads to the synthesis of proteins associated with survival and proliferation [
7‐
9] and to the synthesis of proteins associated with apoptosis [
10]. Using immunohistochemistry, dysregulated RBM3 expression has been suggested as prognostic biomarker in several cancers [
11‐
19].
Only one immunohistochemical study has so far analysed RBM3 expression in upper gastrointestinal adenocarcinomas using a tissue microarray containing of 175 tumor specimens [
12]. The authors suggested a potential prognostic role of altered RBM3 expression in patients with upper gastrointestinal adenocarcinomas [
12]. To better assess the role of RBM expression in esophageal cancers, immunohistochemistry was applied to tissue microarrays containing samples from more than 600 esophageal cancer patients with oncological follow-up data. The present study shows that decreased RBM3 expression is linked to a subset of esophageal cancers with unfavourable tumor phenotype.
Discussion
The data from this study show, that altered RBM3 expression – a strong prognostic feature in several cancer types – is statistically linked to adverse tumor features in oesophageal cancer but does not have an obvious impact on clinical outcome.
The comparative analysis of normal and neoplastic epithelium revealed that RBM3 expression was reduced in a fraction of cancers. These results are in line with data of one earlier study analyzing RBM3 expression in 60 EAC samples [
12]. The authors also found a significantly higher RBM3 expression in normal squamous epithelium as compared to primary tumours [
12].
Earlier studies on RBM3 expression in other malignancies have often indicated a biological and clinical significance of RBM3 expression, but results varied substantially between tumor entities. An increase of RBM3 in malignant relative to corresponding benign tissue has been suggested in gastric [
12], prostate [
11,
17] and breast [
19] cancer. However, a decreased RBM3 expression in cancerous relative to non-cancerous tissue has been reported in colon cancer [
21], malignant melanoma [
16], and urothelial bladder cancer [
14]. These discrepant observations may be due to different interactions between RBM3 and other gene products expressed and activated in individual tissue types.
In vitro studies on the role of RBM proteins in tumorigenesis have also yielded conflicting results and the exact function of RBM3 is still to be fully elucidated. So far, pro-oncogenic as well as tumor suppressive functions of RBM3 have been suggested [
6,
10,
22,
23]. Some studies suggested RBM3 to induce cell proliferation and inhibit the DNA damage response machinery and cell death [
6,
22,
23], while others suggested RBM3 to be positive associated with the pro-apoptotic BAX gene [
10], to be downregulated in an in vitro model of melanoma progression [
24], and to enhance platinum-sensitivity in vitro in ovarian cancer [
18]. Our finding of reduced RBM3 expression being associated with advanced tumor stage in adenocarcinoma of the esophagus is supported by findings of Jonsson et al. [
12] describing a significant association between reduced RBM3 expression and a more aggressive tumor phenotype. Our data further suggest, that RBM3 might play a comparable role in squamous cell carcinomas. In this subset of esophageal cancers, reduced RBM3 expression was statistically linked to adverse tumor features. The fact that reduced RBM3 expression was linked to development of cancer and was associated with adverse tumor features in our study suggests a tumor suppressive rather than an oncogenic role in esophageal cancers. Previously, studies have shown that BAX also plays a critical role in the determination of tumor response to radiation therapy in esophageal carcinoma cells [
25]. Thus, it can be speculated that RBM3 might be also associated to the expression of pro-apoptotic BAX gene in our study. However, the exact mechanism how reduced RBM3 dives esophageal carcinogenesis remains elusive.
However, in our study, RBM3 expression loss has no clinically relevant impact on patient prognosis in both entities. These data disagree with the study of Jonsson et al. [
12] suggesting RBM3 expression as a relevant prognostic marker in a mixed cohort of gastric and esophageal adenocarcinomas. These discrepant results may be due to differences in the patient cohorts. We only included esophageal cancer patients in our study. It can be speculated that the prognostic impact of RBM3 expression in the Jonsson’s mixed cohort of upper gastrointestinal adenocarcinomas, was largely driven by the subset of gastric cancers.
To evaluate whether RBM3 expression is linked to p53 expression in esophageal cancer, our pre-existing database on p53 immunostaining was used. In general, the pathogenesis of esophageal carcinoma is highly complex, involving an accumulation of genetic modifications resulting in invasive carcinoma [
26,
27]. Genetic mutations within the tumour suppressor gene,
TP53, which is involved in DNA repair and cell cycle arrest [
26,
28,
29], is one of the most frequently genetic abnormalities in cancers [
30]. Thus, we next correlated RBM3 expression with pre-existing data on p53 IHC in esophageal cancer. Our results demonstrate that RBM3 expression was unrelated to p53 expression in esophageal cancer samples.
Previously, authors speculated that the analysis of significances between biomarkers and clinical outcome is limited due to tumour heterogeneity [
31] and that the analysis of multiple cores per tumor specimen might enhance the representativity of TMA studies [
32]. These authors suggest that there might exist a better concordance of large section findings with tissue microarrays data, if 3–4 cores were analysed per cancer on comparison to the use of only one core. However, these suggestions were based on the assumption that significant heterogeneity may exist within the tissue represented by a standard 3 × 4 cm paraffin block, and that large section analysis is the method of choice to estimate tumor heterogenity. In our opinion, this assumption is disputable, since previously, data have shown that the TMA format is generally superior over large section studies to analyse potential correlations between molecular markers and the clinical outcome [
33] and that there were found high significances between biomarkers and clinical outcome irrespectively if the three tissue cores were analyzed separately, or if a combined result was generated from the three cores [
34]. These data demonstrate that the use of multiple cores in a TMA does not necessarily enhance the ability to identify significant relationships between biomarkers and tumor phenotype and/or prognosis. Moreover, these data underline the robustness of IHC microtissue array studies for analysis of correlations of molecular markers with clinico-pathological features of cancer specimens.
In summary, our data show that decreased RBM3 expression is associated with unfavourable esophageal cancer phenotype but is unrelated to prognosis of patients. Therefore, RBM3 cannot be considered as a clinically relevant prognostic biomarker in esophageal cancers.